Retrophin Reports Acceptance of Four RE-024 Abstracts Related to Presentation at CPDMD

Retrophin, Inc.

today announced that four abstracts related to the development of RE-024, the company's novel investigational replacement therapy for pantothenate kinase-associated neurodegeneration (PKAN), have been accepted for poster presentation at the 20th International Congress of Parkinson's Disease and Movement Disorders, to be held June 19-23, 2016 in Berlin, Germany. The abstracts include new case reports of two PKAN patients who received RE-024 as part of physician-initiated treatment. "We are pleased that data for RE-024 will be presented at the MDS International Congress," said Alvin Shih, M.D., executive vice president and head of research & development for Retrophin. "The new data from two PKAN patients treated with RE-024 will add to the growing body of evidence supporting clinical development of this investigational therapy for the treatment of PKAN." PKAN is a rare and life-threatening neurodegenerative condition characterized by a host of progressively debilitating movement disorders. There are no approved treatment options for PKAN and current therapeutic strategies focus on symptom management. The following RE-024 abstracts will be presented as part of the congress poster sessions scheduled for June 23, 12:00 – 13:30 p.m. CEST in the Exhibit Hall, Hall B, Level 2: Abstract #2096: "RE-024: Mechanism of Action and Efficacy in Non-Clinical Models" Abstract #2105: "Development of a Human Neuroblastoma Model of Pantothenate Kinase-Associated Neurodegeneration" Abstract #2106: "A Healthy Volunteer Phase 1 Study of RE-024, A Potential Phosphopantothenate Replacement Therapy for Patients with Pantothenate Kinase-Associated Neurodegeneration (PKAN)" Abstract #2108: "RE-024: A Potential Phosphopantothenate Replacement Therapy in 2 Patients with Pantothenate Kinase-Associated Neurodegeneration (PKAN)"